ACRP and ENACCT announced the integration of key ENACCT products and services into the current ACRP professional development portfolio.
The Association of Clinical Research Professionals (ACRP) and the Education Network to Advance Cancer Clinical Trials (ENACCT) announced the integration of key ENACCT products and services into the current ACRP professional development portfolio.
The integration is another step in ACRP's commitment to expand its educational programs and services to enhance the skills of clinical research professionals. Developed over the last 10 years by national experts in the field, the ENACCT programs and services focus on increasing cancer clinical trial participation, particularly within underserved communities. ACRP and ENACCT's integration will see products and services offered by ENACCT transferred to ACRP, which will host these cancer-focused resources among its professional development catalog. ENACCT's integration will allow the formation of a new Clinical Trials Recruitment Interest Group that will allow members to actively engage in open dialogue about challenges and solutions pertinent to this topic.
ACRP will pursue additional resources for creating new and updated content to further serve the interests of the former ENACCT membership and current ACRP community regarding clinical trials accrual and cancer clinical research.
Read the full release here.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.